SPARCC MRI 6 DVU scores for spinal inflammation at baseline and at 12 weeks after randomization to either placebo (n = 16) or infliximab 3 mg/kg (n = 16) in patients with AS.
| Reader | Treatment | Baseline mean (SD) median (25/75 IQ) 95% CI range | Week 12 mean (SD) median (25/75 IQ) 95% CI range | Change mean (SD) median (25/75 IQ) 95% CI range | p |
|---|---|---|---|---|---|
| A | Placebo | 19.00 (16.77) | 18.88 (19.01) | −0.13 (6.98) | 0.0012 |
| 16.50 (4.25/34.75) | 13.00 (1.25/35.50) | 0.0 (−2.75/1.0) | |||
| 10.06, 27.94 | 8.75, 29.00 | −3.84, 3.59 | |||
| 0.0–47.0 | 0.0–58.0 | −18.0 to 15.0 | |||
| A | Infliximab | 18.94 (17.98) | 7.0 (9.89) | −11.94 (12.24) | |
| 13.5 (1.25/41.75) | 1.50 (0.0/10.0) | −9.50 (−16.0/−1.0) | |||
| 9.36, 28.52 | 1.73, 12.27 | −18.46, −5.42 | |||
| 0.0–46.0 | 0.0–32.0 | −39.0 to 0.0 | |||
| B | Placebo | 17.19 (21.43) | 16.69 (21.29) | −0.50 (6.55) | 0.0009 |
| 5.50 (2.00/40.00) | 6.50 (2.00/38.00) | 0.0 (0.0–0.75) | |||
| 5.77, 28.61 | 5.34, 28.03 | −3.99, 2.99 | |||
| 0.0–61.00 | 0.0–62.0 | −23 to 10.0 | |||
| B | Infliximab | 14.13 (16.89) | 3.94 (8.42) | −10.19 (12.07) | |
| 9.00 (0.00/24.00) | 0.00 (0.0/6.00) | −7.00 (−17.00/0.00) | |||
| 5.12, 23.13 | −0.55, 8.42 | −16.62, −3.75 | |||
| 0.00–51.00 | 0.00–33.00 | −36.00 to 0.00 | |||
| C | Placebo | 17.06 (16.04) | 17.19 (17.84) | 0.13 (5.06) | 0.0014 |
| 12.0 (4.25/26.75) | 9.00 (3.25/27.0) | 0.0 (−2.75/1.75) | |||
| 8.52, 25.61 | 7.68, 26.69 | −2.57, 2.82 | |||
| 0.0–52.0 | 0.0–57.0 | −10 to 11.0 | |||
| C | Infliximab | 16.31 (16.60) | 5.44 (9.47) | −10.88 (9.32) | |
| 11.50 (1.75/23.0) | 1.0 (0.0/5.5) | −10.0 (−17.50/−0.25) | |||
| 7.47, 25.16 | 0.39, 10.49 | −15.84, −5.91 | |||
| 0.0–50.0 | 0.0–29.0 | −31 to 0.0 |
SPARCC: Spondyloarthritis Research Consortium of Canada; MRI: magnetic resonance imaging; DVU: discovertebral units; AS: ankylosing spondylitis. IQ: interquartile.